UK Markets open in 4 hrs 43 mins

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.88-0.16 (-1.99%)
At close: 04:00PM EDT
8.17 +0.29 (+3.68%)
After hours: 07:13PM EDT

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees764

Key executives

NameTitlePayExercisedYear born
Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D.CEO, Member of Management Board & MD548.47kN/A1970
Mr. Pierre Kemula B.Sc.MD, CFO & Member of Management Board578.81kN/A1975
Ms. Ulrike Gnad-Vogt M.D., Ph.D.Interim Chief Devel. Officer & Member of Exec. Board221.74kN/A1972
Dr. Igor Splawski M.Sc., Ph.D.Chief Scientific Officer & Member of Management Board410.37kN/A1969
Dr. Antony Blanc Ph.D.MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board353.6kN/A1970
Mr. Malte Greune Ph.D.COO, Member of Management Board & MD337.8kN/A1965
Dr. Sarah FakihVP Corp. Communications & Investor RelationsN/AN/AN/A
Mr. Marco Rau L.L.M., Ph.D.Gen. CounselN/AN/AN/A
Mr. Thorsten SchullerHead of Corp. CommunicationsN/AN/AN/A
Slavica Stevanovic-HeckHead of HRN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Corporate governance

CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.